2019
DOI: 10.1016/j.biochi.2019.01.022
|View full text |Cite
|
Sign up to set email alerts
|

The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
86
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 127 publications
(89 citation statements)
references
References 105 publications
3
86
0
Order By: Relevance
“…DPA is a precursor of a large class of lipid mediators (special proteins, resolvins, maresins, and isoprostanes) mainly taking part in the elimination of inflammation, with specific effects in contrast to other ω-3 PUFAs. The DPA is beneficial for the cardiovascular system and correlates with risk markers of metabolic diseases, especially with parameters of blood lipids, with platelet aggregation, and with insulin sensitivity [118].…”
Section: Omega-3 Polyunsaturated Fatty Acidsmentioning
confidence: 99%
“…DPA is a precursor of a large class of lipid mediators (special proteins, resolvins, maresins, and isoprostanes) mainly taking part in the elimination of inflammation, with specific effects in contrast to other ω-3 PUFAs. The DPA is beneficial for the cardiovascular system and correlates with risk markers of metabolic diseases, especially with parameters of blood lipids, with platelet aggregation, and with insulin sensitivity [118].…”
Section: Omega-3 Polyunsaturated Fatty Acidsmentioning
confidence: 99%
“…However, DPA is of current interest both for its ability to increase EPA and DHA tissue status, and for its specific or shared biological effects. Moreover, DPA is the most abundant LC-PUFA in the brain after DHA, and it could be specifically beneficial for the elderly neuroprotection and early-life development [56].…”
Section: Lipid Profile and Adequacymentioning
confidence: 99%
“…High levels of common polyunsaturated fatty acids, such as EPA and DHA, favor the replacement of arachidonic acid within the phospholipids of the cell membrane [52]. This decreases the binding of arachidonic acid on cyclooxygenase 1, reducing the synthesis of thromboxane A2, which is considered as an element that increases platelet aggregation and vasoconstriction [52,53]. The approach also produces Thromboxane A3, which exerts a low biological effect compared to thromboxane A2.…”
Section: Impact Of ω-3 and ω-6 Pufas In Thrombogenesismentioning
confidence: 99%